Olatec

Olatec is a privately held biopharmaceutical company headquartered in New York, United States, with additional operations and offices in the Netherlands. The company is dedicated to improving the health and physical well-being of patients worldwide through the development and commercialization of a platform of safe and effective pharmaceuticals that treat a broad spectrum of inflammatory diseases. Its core scientific focus is the innate immune system, specifically the NLRP3 inflammasome, which the company describes as the body's first-line response in innate immunity. Olatec's lead compound is dapansutrile, known by the laboratory code OLT1177®. OLT1177® is a pharmaceutical-grade form of dapansutrile and is a registered trademark of Olatec Therapeutics in the United States and other countries. By selectively targeting NLRP3, dapansutrile inhibits the production of the pro-inflammatory cytokines IL-1β and IL-18. The company states that its platform is intended to address significant unmet needs in the treatment of acute and chronic inflammatory diseases known to be mediated by Interleukin-1 (IL-1). These include arthritis, heart failure, asthma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, spinal cord injury, type-2 diabetes, melanoma, and breast cancers, among others. According to the company, dapansutrile is in Phase 2 clinical trials in the United States and Europe. Beyond dapansutrile, Olatec's platform includes more than 40 structurally related compounds referred to as OLT Analogues. The company believes that based on clinical results and the expected market advantages of dapansutrile, as well as data being generated from the OLT Analogues, its platform has the potential not only to transform and expand markets but also to represent a new class of pharmaceuticals for the treatment of inflammatory diseases mediated by IL-1. Olatec's drug development team, which the company says has worked together over 10 years, is comprised of experienced management and international thought leaders with expertise in inflammation and immunology. The company maintains a leadership structure that includes management, a Scientific Advisory Board, a Clinical Advisory Board, and a Board of Directors. Olatec conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. It is a privately held company and does not appear to be listed on any public stock exchange. The company also actively protects its OLT1177 trademark, warning that unauthorized manufacturers claiming to offer OLT1177 have been shown to have inferior product quality, including lower potency and greater impurities, which may adversely impact the outcomes and safety of preclinical scientific research.

Olatec is a privately held biopharmaceutical company based in New York, United States, with operations and offices also in the Netherlands. The company was founded to develop and commercialize a platform of safe and effective pharmaceuticals for a broad spectrum of inflammatory diseases. Its scientific foundation rests on targeting the NLRP3 inflammasome, a component of the innate immune system that the company describes as the body's first-line response. The company's lead compound, dapansutrile (laboratory code OLT1177®), is a selective NLRP3 antagonist designed to inhibit the production of the pro-inflammatory cytokines IL-1β and IL-18. Olatec states that its drug development team has worked together for over 10 years and includes experienced management and international thought leaders with expertise in inflammation and immunology who have been involved in the discovery and development of first-line inflammation treatments currently on the market. Olatec has advanced dapansutrile into Phase 2 clinical trials in both the United States and Europe. The company's platform also includes more than 40 structurally related compounds, known as OLT Analogues, which are being studied for their potential in treating inflammatory diseases mediated by IL-1. Olatec positions its platform as having the potential to transform and expand markets and to represent a new class of pharmaceuticals for inflammatory diseases. The company maintains a structured leadership and advisory framework, including a management team, a Scientific Advisory Board, a Clinical Advisory Board, and a Board of Directors. It conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. As a privately held company, Olatec does not appear on public stock exchanges. It actively enforces its OLT1177® trademark, warning that unauthorized products claiming to be OLT1177 have shown inferior quality, including lower potency and greater impurities, which could adversely affect preclinical research outcomes and safety.

• Olatec's drug development team has worked together for over 10 years, according to the company.

• Dapansutrile (OLT1177®) advances into Phase 2 clinical trials in the United States and Europe.

A leader in the clinical development of safe and effective NLRP3 inhibitors addressing a broad spectrum of inflammatory diseases.

• dapansutrile (OLT1177®)

  A selective NLRP3 antagonist and the company's lead compound, in Phase 2 clinical trials in the US and Europe. It inhibits the production of pro-inflammatory cytokines IL-1β and IL-18.

• OLT Analogues

  More than 40 structurally related compounds that form part of Olatec's pharmaceutical platform.

1. 1Olatec - Homeolatec.com
2. 2Products - Olatecolatec.com
3. 3Olatec (United States) - Wikidatawikidata.org